Literature DB >> 20713528

FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.

Santosh Gupta1, Kristiina Iljin, Henri Sara, John Patrick Mpindi, Tuomas Mirtti, Paula Vainio, Juha Rantala, Kalle Alanen, Matthias Nees, Olli Kallioniemi.   

Abstract

TMPRSS2-ERG and other gene fusions involving ETS factors and genes with strong promoter elements are common in prostate cancer. Although ERG activation has been linked to invasive properties of prostate cancers, the precise mechanisms and pathways of ERG-mediated oncogenesis remain poorly understood. Here, we show that ERG knockdown in VCaP prostate cancer cells causes an activation of cell adhesion, resulting in strongly induced active beta(1)-integrin and E-cadherin expression as well as changes in WNT signaling. These observations were corroborated by data from ERG-overexpressing nontransformed prostate epithelial cells as well as gene expression data from clinical prostate cancer samples, which both indicated a link between ERG and epithelial-to-mesenchymal transition (EMT). Upregulation of several WNT pathway members was seen in ERG-positive prostate cancers, with frizzled-4 (FZD4) showing the strongest overexpression as verified by both reverse transcription-PCR and immunostaining. Both ERG knockin and knockdown modulated the levels of FZD4 expression. FZD4 silencing could mimic the ERG knockdown phenotype by inducing active beta(1)-integrin and E-cadherin expression, whereas FZD4 overexpression reversed the phenotypic effects seen with ERG knockdown. Taken together, our results provide mechanistic insights to ERG oncogenesis in prostate cancer, involving activation of WNT signaling through FZD4, leading to cancer-promoting phenotypic effects, including EMT and loss of cell adhesion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713528     DOI: 10.1158/0008-5472.CAN-10-0244

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  132 in total

1.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

Review 2.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

3.  Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Authors:  Yiwei Li; Dejuan Kong; Zhiwei Wang; Aamir Ahmad; Bin Bao; Subhash Padhye; Fazlul H Sarkar
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

4.  The ERGonomics of hematopoietic stem cell self-renewal.

Authors:  Scott A Lacadie; Leonard I Zon
Journal:  Genes Dev       Date:  2011-02-15       Impact factor: 11.361

5.  Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy.

Authors:  Andrew J Armstrong; Stephen J Freedland; Mariano Garcia-Blanco
Journal:  Asian J Androl       Date:  2011-01-03       Impact factor: 3.285

6.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

7.  RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.

Authors:  Shiguang Cao; Ruiying Sun; Wei Wang; Xia Meng; Yuping Zhang; Na Zhang; Shuanying Yang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

10.  Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.

Authors:  Yanyuan Wu; Charles Ginther; Juri Kim; Nicole Mosher; Seyung Chung; Dennis Slamon; Jaydutt V Vadgama
Journal:  Mol Cancer Res       Date:  2012-10-15       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.